Consortium partners

consortium-ppl 

Université de Genève, Department of Pathology and Immunology (UNIGE)

Université de Genève, Department of Pathology and Immunology (UNIGE)

Further Information : http://www.unige.ch/

Organizational Activities

The Université de Genève was founded in 1559 and is today the second most important University of Switzerland. UNIGE provides state-of-the-art infrastructure for research (animal facilities, genomic, proteomics and imaging platforms and clinical research center). A large part of the research performed in the laboratory of Prof. Krause of the Department of Pathology and Immunology focuses on the role of NOX enzymes in pathophysiological situations. Several NOX isoforms were discovered in this lab and NOX1 and NOX4 knock-out mice were generated.

UNIGE is the coordinator of NEURINOX and as such in charge of the scientific management and representation of the project. UNIGE has a longstanding expertise in NOX enzymes and has recently identified the role played by NOX2 in CNS pathologies.

Role in the Project

Key Personnel

Karl-Heinz Krause, NEURINOX project coordinator, is Professor of Medicine at the Department of Pathology and Immunology of the Faculty of Medicine and the University Hospitals in Geneva. Throughout his career, he received strong competitive grant support from national and international agencies and his work has is highly cited (~900 citations in 2010; H index 50). He was also the organizer of several international meetings, including the first Gordon Research Conference on "NOX family NADPH oxidases".

NEURINOX

Vincent Jaquet, NEURINOX scientific manager, is Lecturer at the Department of Pathology and Immunology of the Faculty of Medicine. He holds a PhD since 1997 from the University of Lausanne. He joined the laboratory of Professor Karl-Heinz Krause in 2005 where he specialized on the pharmacology of NOX enzymes, methods of ROS detection and NOX inhibitors.

NEURINOX

Tamara Seredenina, PhD. Postdoc at UNIGE, in charge of project regarding NOX enzymes in in vitro and in vivo models of ALS. She holds a PhD since 2006 from Russian State Medical University. In her previous positions, she was involved in identification and validation of novel drug targets for the treatment of Alzheimer’s and Huntington’s diseases.

NEURINOX